[
  {
    "ts": null,
    "headline": "Markets Weekly Outlook - U.S. Services PMI, Bank Of England Rate Decision And Canadian/NZ Employment",
    "summary": "Markets Weekly Outlook - U.S. Services PMI, Bank Of England Rate Decision And Canadian/NZ Employment",
    "url": "https://finnhub.io/api/news?id=323e482af5b452ee03ec96f127fa4ea9cfcb9a3baa730247ca7afe1fe44cdbfe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754089500,
      "headline": "Markets Weekly Outlook - U.S. Services PMI, Bank Of England Rate Decision And Canadian/NZ Employment",
      "id": 136179677,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=323e482af5b452ee03ec96f127fa4ea9cfcb9a3baa730247ca7afe1fe44cdbfe"
    }
  },
  {
    "ts": null,
    "headline": "Earnings, Fed commentary, consumer credit: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch this weekend, starting Saturday, Aug. 2, and next week, starting Monday, Aug. 4. This Saturday, Berkshire Hathaway (BRK-B, BRK-A) is releasing quarterly results. Next week, a host of quarterly earnings will be posted: Monday: Palantir (PLTR) and Hims & Hers (HIMS) Tuesday: Pfizer (PFE), Advanced Micro Devices (AMD), and Rivian (RIVN) Wednesday: Novo Nordisk (NVO), Disney (DIS), McDonald's (MCD), Uber (UBER), and Lyft (LYFT) Thursday: Eli Lilly (LLY), Toyota (TM), and Warner Bros. Discovery (WBD) We will be getting fresh Federal Reserve commentary on Thursday when Atlanta Fed President Raphael Bostic delivers remarks. This comes Consumer credit data for the month of June will be posted in the afternoon. Economists are expecting an increase from the prior month. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=04dd52ad3909f8fce86a767476ce0b4ef78f2de3765240d229258feabc612248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754086503,
      "headline": "Earnings, Fed commentary, consumer credit: What to Watch",
      "id": 136180619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch this weekend, starting Saturday, Aug. 2, and next week, starting Monday, Aug. 4. This Saturday, Berkshire Hathaway (BRK-B, BRK-A) is releasing quarterly results. Next week, a host of quarterly earnings will be posted: Monday: Palantir (PLTR) and Hims & Hers (HIMS) Tuesday: Pfizer (PFE), Advanced Micro Devices (AMD), and Rivian (RIVN) Wednesday: Novo Nordisk (NVO), Disney (DIS), McDonald's (MCD), Uber (UBER), and Lyft (LYFT) Thursday: Eli Lilly (LLY), Toyota (TM), and Warner Bros. Discovery (WBD) We will be getting fresh Federal Reserve commentary on Thursday when Atlanta Fed President Raphael Bostic delivers remarks. This comes Consumer credit data for the month of June will be posted in the afternoon. Economists are expecting an increase from the prior month. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=04dd52ad3909f8fce86a767476ce0b4ef78f2de3765240d229258feabc612248"
    }
  },
  {
    "ts": null,
    "headline": "McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week",
    "summary": "Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over the next week. This past week featured results from four companies in the “Magnificent Seven,” plus President Trump’s reciprocal tariff deadline and a weak July jobs report.",
    "url": "https://finnhub.io/api/news?id=20f37e84e3ea0fbc2542950aab83c2d82c3e92cb8fff948d49d35fdc27977af2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754080716,
      "headline": "McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week",
      "id": 136183225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over the next week. This past week featured results from four companies in the “Magnificent Seven,” plus President Trump’s reciprocal tariff deadline and a weak July jobs report.",
      "url": "https://finnhub.io/api/news?id=20f37e84e3ea0fbc2542950aab83c2d82c3e92cb8fff948d49d35fdc27977af2"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View",
    "summary": "MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.",
    "url": "https://finnhub.io/api/news?id=3a49c8107c123b7e307fa0aa7ceac15cabef1164d8a32652eaaac694eca1fee5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754068860,
      "headline": "MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View",
      "id": 136183324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.",
      "url": "https://finnhub.io/api/news?id=3a49c8107c123b7e307fa0aa7ceac15cabef1164d8a32652eaaac694eca1fee5"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: BP, Diageo, Disney, Uber and WPP",
    "summary": "Earnings preview of key companies reporting next week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=8f6d19339cc79d3a0f38348d569e04f911548737030e6518d7b7f19b9bc82e26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754062721,
      "headline": "Stocks to watch next week: BP, Diageo, Disney, Uber and WPP",
      "id": 136165211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting next week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=8f6d19339cc79d3a0f38348d569e04f911548737030e6518d7b7f19b9bc82e26"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings",
    "summary": "PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.",
    "url": "https://finnhub.io/api/news?id=bd2348076c139f70484ae35e21067cfef1c5a501917f4279cd5024e209cee273",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056860,
      "headline": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings",
      "id": 136165215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.",
      "url": "https://finnhub.io/api/news?id=bd2348076c139f70484ae35e21067cfef1c5a501917f4279cd5024e209cee273"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
    "summary": "These pharmaceutical giants are well worth a second look.",
    "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056800,
      "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
      "id": 136165216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These pharmaceutical giants are well worth a second look.",
      "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
    "summary": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
    "url": "https://finnhub.io/api/news?id=79abc80ff93d4138ec08bf76d30e0cf991efa8dba6556a16ccbb396e2d89a90d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754054729,
      "headline": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
      "id": 136167523,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=79abc80ff93d4138ec08bf76d30e0cf991efa8dba6556a16ccbb396e2d89a90d"
    }
  },
  {
    "ts": null,
    "headline": "Moderna's Key Patent Win Overshadowed By Gloomy Outlook",
    "summary": "Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million. Sales fell 41% from $241 million in the same period in 2024. The decline was primarily driven by lower COVID-19 vaccine sales, which totaled $114 million in the quarter. Also Read: Robert Kennedy Jr Blasts Vaccine",
    "url": "https://finnhub.io/api/news?id=212fa4f3d46b9e154a74420c485eefe25fcc53dce03633dfcea5fb8e55225e1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754052295,
      "headline": "Moderna's Key Patent Win Overshadowed By Gloomy Outlook",
      "id": 136165497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million. Sales fell 41% from $241 million in the same period in 2024. The decline was primarily driven by lower COVID-19 vaccine sales, which totaled $114 million in the quarter. Also Read: Robert Kennedy Jr Blasts Vaccine",
      "url": "https://finnhub.io/api/news?id=212fa4f3d46b9e154a74420c485eefe25fcc53dce03633dfcea5fb8e55225e1f"
    }
  },
  {
    "ts": null,
    "headline": "Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options",
    "summary": "Fibromyalgia, a complex chronic pain disorder marked by widespread pain, fatigue, and cognitive issues, is witnessing evolving treatment advancements. The global market is experiencing growth through novel drugs targeting central sensitization, increased use of digital health tools, and personalized medicine. Enhanced diagnostic criteria are aiding improved disease management, although challenges like underdiagnosis and limited treatment efficacy persist. Key areas like North America and Europe",
    "url": "https://finnhub.io/api/news?id=e13ac23a2d216dd7614073e2f624b836e3acc1520eed340025bbc9e600885109",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754038800,
      "headline": "Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options",
      "id": 136165282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Fibromyalgia, a complex chronic pain disorder marked by widespread pain, fatigue, and cognitive issues, is witnessing evolving treatment advancements. The global market is experiencing growth through novel drugs targeting central sensitization, increased use of digital health tools, and personalized medicine. Enhanced diagnostic criteria are aiding improved disease management, although challenges like underdiagnosis and limited treatment efficacy persist. Key areas like North America and Europe",
      "url": "https://finnhub.io/api/news?id=e13ac23a2d216dd7614073e2f624b836e3acc1520eed340025bbc9e600885109"
    }
  },
  {
    "ts": null,
    "headline": "Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Emerging Trends Highlight Shift Towards Immunotherapy in Testicular Cancer",
    "summary": "Testicular cancer, primarily affecting men aged 15-35, is witnessing advancements that significantly impact diagnosis and treatment outcomes. As the most common cancer in young men, early detection, primarily via ultrasound and blood tests, is critical, boasting over a 95% survival rate in localized cases. The market is growing due to heightened awareness, novel therapies, and personalization in treatment approaches by leading companies like Pfizer, Merck, and Roche. Challenges include high trea",
    "url": "https://finnhub.io/api/news?id=6a2ae63fc85eda204704834e50188b4d089145d42820650384a199a85c7f3c53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754038260,
      "headline": "Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Emerging Trends Highlight Shift Towards Immunotherapy in Testicular Cancer",
      "id": 136165372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Testicular cancer, primarily affecting men aged 15-35, is witnessing advancements that significantly impact diagnosis and treatment outcomes. As the most common cancer in young men, early detection, primarily via ultrasound and blood tests, is critical, boasting over a 95% survival rate in localized cases. The market is growing due to heightened awareness, novel therapies, and personalization in treatment approaches by leading companies like Pfizer, Merck, and Roche. Challenges include high trea",
      "url": "https://finnhub.io/api/news?id=6a2ae63fc85eda204704834e50188b4d089145d42820650384a199a85c7f3c53"
    }
  },
  {
    "ts": null,
    "headline": "Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases",
    "summary": "Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innova",
    "url": "https://finnhub.io/api/news?id=e52353e274c9e47c5cb25f66391671b7e07291da485e59ee4d235401e742eb2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754037000,
      "headline": "Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases",
      "id": 136165283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innova",
      "url": "https://finnhub.io/api/news?id=e52353e274c9e47c5cb25f66391671b7e07291da485e59ee4d235401e742eb2e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Demands Pharma Companies to Lower US Prices",
    "summary": "US President Donald Trump sent letters to 17 of the world's largest pharmaceutical companies demanding they charge the US what other countries pay for new medicines. In the letters, sent to Eli Lilly, Novo Nordisk, Pfizer and others, Trump insisted companies immediately lower what they charge Medicaid for existing drugs. Bloomberg Intelligence's Sam Fazeli breaks down the situation.",
    "url": "https://finnhub.io/api/news?id=64883fd0280805f67ba0b66f53c1526eda9f60f1790b2c7e924e88d651b8420c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754034632,
      "headline": "Trump Demands Pharma Companies to Lower US Prices",
      "id": 136165222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US President Donald Trump sent letters to 17 of the world's largest pharmaceutical companies demanding they charge the US what other countries pay for new medicines. In the letters, sent to Eli Lilly, Novo Nordisk, Pfizer and others, Trump insisted companies immediately lower what they charge Medicaid for existing drugs. Bloomberg Intelligence's Sam Fazeli breaks down the situation.",
      "url": "https://finnhub.io/api/news?id=64883fd0280805f67ba0b66f53c1526eda9f60f1790b2c7e924e88d651b8420c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech -- Update",
    "summary": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech -- Update",
    "url": "https://finnhub.io/api/news?id=89212ce44910addeae64158036416a8cbdefc1e1f8508e731b394964d9983f46",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754033460,
      "headline": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech -- Update",
      "id": 136169772,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech -- Update",
      "url": "https://finnhub.io/api/news?id=89212ce44910addeae64158036416a8cbdefc1e1f8508e731b394964d9983f46"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech",
    "summary": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech",
    "url": "https://finnhub.io/api/news?id=1b0d36b324d6cac456d08e1d3dfa6b2c17658920abf20f48d40849e0a4cf56e3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754030760,
      "headline": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech",
      "id": 136169773,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech",
      "url": "https://finnhub.io/api/news?id=1b0d36b324d6cac456d08e1d3dfa6b2c17658920abf20f48d40849e0a4cf56e3"
    }
  },
  {
    "ts": null,
    "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
    "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
    "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754008407,
      "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
      "id": 136160868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
      "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c"
    }
  }
]